FIG 5.

Treatment status of ≥ 5-year survivors treated with (A) nivolumab and (B) docetaxel. Timing of only the first administered subsequent therapy is noted, patients may have received ≥ 1 subsequent treatment. ^aPatient received radiotherapy prior to discontinuation of nivolumab; ^bPatient received radiotherapy in addition to nivolumab; ^cPatient withdrew consent, and so subsequent treatment status is unknown. ^dPatient response note reported. CR, complete response; No., number; PD, progressive disease; PR, partial response.